Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors

Background: We examined longitudinally the course and predictors of treatment resistance in a large cohort of first-episode psychosis (FEP) patients from initiation of antipsychotic treatment. We hypothesized that antipsychotic treatment resistance is: (a) present at illness onset; and (b) differentially associated with clinical and demographic factors. Method: The study sample comprised 323 FEP patients who were studied at first contact and at 10-year follow-up. We collated clinical information on severity of symptoms, antipsychotic medication and treatment adherence during the follow-up period to determine the presence, course and predictors of treatment resistance. Results: From the 23% of the patients, who were treatment resistant, 84% were treatment resistant from illness onset. Multivariable regression analysis revealed that diagnosis of schizophrenia, negative symptoms, younger age at onset, and longer duration of untreated psychosis predicted treatment resistance from illness onset. Conclusions: The striking majority of treatment-resistant patients do not respond to first-line antipsychotic treatment even at time of FEP. Clinicians must be alert to this subgroup of patients and consider clozapine treatment as early as possible during the first presentation of psychosis

The role of pressure anisotropy in the turbulent intracluster medium

In low-density plasma environments, such as the intracluster medium (ICM), the Larmour frequency is much larger than the ion-ion collision frequency. In such a case, the thermal pressure becomes anisotropic with respect to the magnetic field orientation and the evolution of the turbulent gas is more correctly described by a kinetic approach. A possible description of these collisionless scenarios is given by the so-called kinetic magnetohydrodynamic (KMHD) formalism, in which particles freely stream along the field lines, while moving with the field lines in the perpendicular direction. In this way a fluid-like behavior in the perpendicular plane is restored. In this work, we study fast growing magnetic fluctuations in the smallest scales which operate in the collisionless plasma that fills the ICM. In particular, we focus on the impact of a particular evolution of the pressure anisotropy and its implications for the turbulent dynamics of observables under the conditions prevailing in the ICM. We present results from numerical simulations and compare the results which those obtained using an MHD formalism.Comment: 7 pages, 14 figures, Journal of Physics: Conference Serie

The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers

Background: Cannabidiol has potential therapeutic benefits for people with psychiatric disorders characterised by reward function impairment. There is existing evidence that cannabidiol may influence some aspects of reward processing. However, it is unknown whether cannabidiol acutely affects brain function underpinning reward anticipation and feedback. Hypotheses: We predicted that cannabidiol would augment brain activity associated with reward anticipation and feedback. Methods: We administered a single 600 mg oral dose of cannabidiol and matched placebo to 23 healthy participants in a double-blind, placebo-controlled, repeated-measures design. We employed the monetary incentive delay task during functional magnetic resonance imaging to assay the neural correlates of reward anticipation and feedback. We conducted whole brain analyses and region-of-interest analyses in pre-specified reward-related brain regions. Results: The monetary incentive delay task elicited expected brain activity during reward anticipation and feedback, including in the insula, caudate, nucleus accumbens, anterior cingulate and orbitofrontal cortex. However, across the whole brain, we did not find any evidence that cannabidiol altered reward-related brain activity. Moreover, our Bayesian analyses showed that activity in our regions-of-interest was similar following cannabidiol and placebo. Additionally, our behavioural measures of motivation for reward did not show a significant difference between cannabidiol and placebo. Discussion: Cannabidiol did not acutely affect the neural correlates of reward anticipation and feedback in healthy participants. Future research should explore the effects of cannabidiol on different components of reward processing, employ different doses and administration regimens, and test its reward-related effects in people with psychiatric disorders

The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study

Rationale: There is growing interest in the therapeutic potential of cannabidiol (CBD) across a range of psychiatric disorders. CBD has been found to reduce anxiety during experimentally induced stress in anxious individuals and healthy controls. However, the mechanisms underlying the putative anxiolytic effects of CBD are unknown. // Objectives: We sought to investigate the behavioural and neural effects of a single dose of CBD vs. placebo on a range of emotion-related measures to test cognitive-mechanistic models of its effects on anxiety. // Methods: We conducted a randomised, double-blind, placebo-controlled, crossover, acute oral challenge of 600 mg of CBD in 24 healthy participants on emotional processing, with neuroimaging (viewing emotional faces during functional magnetic resonance imaging) and cognitive (emotional appraisal) measures as well as subjective response to experimentally induced anxiety. // Results: CBD did not produce effects on brain responses to emotional faces and cognitive measures of emotional processing, or modulate experimentally induced anxiety, relative to placebo. // Conclusions: Given the rising popularity of CBD for its putative medical benefits, these findings question whether further research is warranted to investigate the clinical potential of CBD for the treatment of anxiety disorders

Mechanisms underlying exercise intolerance in long COVID: An accumulation of multisystem dysfunction

The pathogenesis of exercise intolerance and persistent fatigue which can follow an infection with the SARS-CoV-2 virus ("long COVID") is not fully understood. Cases were recruited from a long COVID clinic (N = 32; 44 ± 12 years; 10 (31%) men), and age-/sex-matched healthy controls (HC) (N = 19; 40 ± 13 years; 6 (32%) men) from University College London staff and students. We assessed exercise performance, lung and cardiac function, vascular health, skeletal muscle oxidative capacity, and autonomic nervous system (ANS) function. Key outcome measures for each physiological system were compared between groups using potential outcome means (95% confidence intervals) adjusted for potential confounders. Long COVID participant outcomes were compared to normative values. When compared to HC, cases exhibited reduced oxygen uptake efficiency slope (1847 (1679, 2016) vs. 2176 (1978, 2373) mL/min, p = 0.002) and anaerobic threshold (13.2 (12.2, 14.3) vs. 15.6 (14.4, 17.2) mL/kg/min, p < 0.001), and lower oxidative capacity, measured using near infrared spectroscopy (τ: 38.7 (31.9, 45.6) vs. 24.6 (19.1, 30.1) s, p = 0.001). In cases, ANS measures fell below normal limits in 39%. Long COVID is associated with reduced measures of exercise performance and skeletal muscle oxidative capacity in the absence of evidence of microvascular dysfunction, suggesting mitochondrial pathology. There was evidence of attendant ANS dysregulation in a significant proportion. These multisystem factors might contribute to impaired exercise tolerance in long COVID sufferers

CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings

Background: Clozapine is an antipsychotic drug with unique efficacy, and it is the only recommended treatment for treatment-resistant schizophrenia (TRS: failure to respond to at least two different antipsychotics). However, clozapine is also associated with a range of adverse effects which restrict its use, including blood dyscrasias, for which haematological monitoring is required. As treatment resistance is recognised earlier in the illness, the question of whether clozapine should be prescribed in children and young people is increasingly important. However, most research to date has been in older, chronic patients, and evidence regarding the efficacy and safety of clozapine in people under age 25 is lacking. The CLEAR (CLozapine in EARly psychosis) trial will assess whether clozapine is more effective than treatment as usual (TAU), at the level of clinical symptoms, patient rated outcomes, quality of life and cost-effectiveness in people below 25 years of age. Additionally, a nested biomarker study will investigate the mechanisms of action of clozapine compared to TAU. // Methods and design: This is the protocol of a multi-centre, open label, blind-rated, randomised controlled effectiveness trial of clozapine vs TAU (any other oral antipsychotic monotherapy licenced in the British National Formulary) for 12 weeks in 260 children and young people with TRS (12–24 years old). // Aim and objectives: The primary outcome is the change in blind-rated Positive and Negative Syndrome Scale scores at 12 weeks from baseline. Secondary outcomes include blind-rated Clinical Global Impression, patient-rated outcomes, quality of life, adverse effects, and treatment adherence. Patients will be followed up for 12 months and will be invited to give consent for longer term follow-up using clinical records and potential re-contact for further research. For mechanism of action, change in brain magnetic resonance imaging (MRI) biomarkers and peripheral inflammatory markers will be measured over 12 weeks. // Discussion: The CLEAR trial will contribute knowledge on clozapine effectiveness, safety and cost-effectiveness compared to standard antipsychotics in young people with TRS, and the results may guide future clinical treatment recommendation for early psychosis. // Trial registration: ISRCTN Number: 37176025, IRAS Number: 1004947. // Trial status: In set-up. Protocol version 4.0 01/08/23. Current up to date protocol available here: https://fundingawards.nihr.ac.uk/award/NIHR131175#/

VORTICITY, SHOCKS, AND MAGNETIC FIELDS IN SUBSONIC, ICM- LIKE TURBULENCE

We analyze data from high resolution simulations of the generation of compressible, MHD turbulence with properties chosen to resemble conditions in galaxy clusters. In particular, the flow is driven to have turbulence Mach number M-t similar to 1/2 in an isothermal medium with an initially very weak, uniform seed magnetic field (beta = P-g/P-B= 10(6)). Since cluster turbulence is likely to result from a mix of sheared (solenoidal) and compressive forcing processes, we examine the distinct turbulence properties for both cases. In one set of simulations velocity forcing is entirely solenoidal (del . delta u= 0), while in the other it is entirely compressive (del x delta u = 0). Both cases develop a mixture of solenoidal and compressive turbulent motions, since each generates the other. The development of compressive turbulent motions leads to shocks, even when the turbulence is solenoidally forced and subsonic. Shocks, in turn, produce and amplify vorticity, which is especially important in compressively forced turbulence. To clarify those processes we include a pair of appendices that look in detail at vorticity evolution in association with shocks. From our simulation analyses we find that magnetic fields amplified to near saturation levels in predominantly solenoidal turbulence can actually enhance vorticity on small scales by concentrating and stabilizing shear. The properties, evolution rates, and relative contributions of the kinetic and magnetic turbulent elements depend strongly on the character of the forcing. Specifically, shocks are stronger, but vorticity evolution and magnetic field amplification are slower and weaker when the turbulence is compressively forced. We identify a simple relation to estimate characteristic shock strengths in terms of the turbulence Mach number and the character of the forcing. Our results will be helpful in understanding flow motions in galaxy clustersopen10

Magnetic fields in cosmic particle acceleration sources

We review here some magnetic phenomena in astrophysical particle accelerators associated with collisionless shocks in supernova remnants, radio galaxies and clusters of galaxies. A specific feature is that the accelerated particles can play an important role in magnetic field evolution in the objects. We discuss a number of CR-driven, magnetic field amplification processes that are likely to operate when diffusive shock acceleration (DSA) becomes efficient and nonlinear. The turbulent magnetic fields produced by these processes determine the maximum energies of accelerated particles and result in specific features in the observed photon radiation of the sources. Equally important, magnetic field amplification by the CR currents and pressure anisotropies may affect the shocked gas temperatures and compression, both in the shock precursor and in the downstream flow, if the shock is an efficient CR accelerator. Strong fluctuations of the magnetic field on scales above the radiation formation length in the shock vicinity result in intermittent structures observable in synchrotron emission images. Resonant and non-resonant CR streaming instabilities in the shock precursor can generate mesoscale magnetic fields with scale-sizes comparable to supernova remnants and even superbubbles. This opens the possibility that magnetic fields in the earliest galaxies were produced by the first generation Population III supernova remnants and by clustered supernovae in star forming regions.Comment: 30 pages, Space Science Review